linsidomine has been researched along with Hypertrophy in 2 studies
linsidomine: RN given refers to parent cpd; structure
Hypertrophy: General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, H | 1 |
| Fang, Q | 1 |
| Wang, M | 2 |
| Wang, W | 1 |
| Zhang, M | 2 |
| Zhang, D | 2 |
| He, Y | 2 |
| Zhang, Y | 2 |
| Wang, H | 1 |
| Otero, M | 2 |
| Ma, T | 1 |
| Chen, J | 2 |
| Jiang, Z | 1 |
2 other studies available for linsidomine and Hypertrophy
| Article | Year |
|---|---|
FGF8 and FGFR3 are up-regulated in hypertrophic chondrocytes: Association with chondrocyte death in deep zone of Kashin-Beck disease.
Topics: Animals; Biomarkers; Cartilage, Articular; Cell Death; Cell Differentiation; Cell Line; Child; Child | 2018 |
3-morpholinosydnonimine (SIN-1)-induced oxidative stress leads to necrosis in hypertrophic chondrocytes in vitro.
Topics: Animals; Apoptosis; Cartilage; Case-Control Studies; Cell Line; Cell Survival; Chondrocytes; Dose-Re | 2018 |